Abstracts tagged "immunology"

Abstract Number: 2461 • ACR Convergence 2025
Targeting treatment-resistant Systemic Lupus Erythematosus through transcriptome-informed drug repurposing
Alexandra Ainatzoglou¹, Georgia-Savina Moysidou², Danae-Mona Nöthling³, Fanouriakis Antonis⁴, George Bertsias⁵, Panagiotis Garantziotis³, Georg Schett⁶ and Dimitrios Boumpas⁷, ¹⁴th Department of Internal Medicine, Attikon University Hospital, National and Kapodistrian University of Athens Medical School, Athens, Athens, Greece, ²Sorbonne université, Service de rhumatologie, groupe hospitalier Pitié-Salpêtrière, Assistance publique-Hôpitaux de Paris, Athens, Greece, ³Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, ⁴National and Kapodistrian University of Athens Medical School, Athens, Greece, Athens, Greece, ⁵Rheumatology and Clinical Immunology, University Hospital of Heraklion and University of Crete Medical School and Foundation for Research and Technology-Hellas (FORTH), Infections and Immunity, Institute of Molecular Biology and Biotechnology, Heraklion, Greece, ⁶Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Germany, ⁷Joint Rheumatology Program, University of Athens Medical School, Athens, Greece
Background/Purpose: Systemic lupus erythematosus (SLE) therapies elicit distinct transcriptional responses, yet a subset of patients fails to achieve clinical remission. To guide precision repurposing, we…
Abstract Number: 0236 • ACR Convergence 2025
Safety and Efficacy of T Cell Engager Therapy in patients with refractory Autoimmune Disease
Laura Bucci¹, Sebastian Böltz¹, Melanie Hagen¹, Danae-Mona Nöthling¹, Tobias Rothe², Carlo Tur¹, Andreas Wirsching¹, Janina Auth³, jochen wacker¹, Markus Eckstein⁴, Stefano Alivernini⁵, Aline Bozec¹, Christina Bergmann¹, Maria Antonietta D'Agostino⁶, Maria Gabriella Raimondo¹, Georg Schett⁷ and Ricardo Grieshaber-Bouyer⁸, ¹Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, ²Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlagen, Germany, ³Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Bayern, Germany, ⁴Institute of Pathology and Comprehensive Cancer Center EMN, Friedrich-Alexander- Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, ⁵Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, ⁶Division of Rheumatology and Clinical Immunology - Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, ⁷Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Germany, ⁸University Hospital Erlangen, Erlangen, Germany
Background/Purpose: T cell engagers (TCEs) are a promising therapeutic strategy to treat autoimmune diseases (AID). However, long-term data remain limited.Methods: Patients with treatment-refractory AID were…
Abstract Number: 0555 • ACR Convergence 2025
Phase 3 Results From an Innovative Trial Design of Treating Plaque Psoriasis Involving Difficult-to-Treat, High-Impact Sites With Icotrokinra, a Targeted Oral Peptide That Selectively Inhibits the IL-23–Receptor
Melinda J. Gooderham¹, Edward Lain², Robert Bissonnette³, Yu-Huei Huang⁴, Charles Lynde⁵, Matthias Hoffmann⁶, Joseph F Merola⁷, Eingun J. Song⁸, Jessica H. Rubens⁹, Amy M. DeLozier⁹, Ming-Chun Hsu⁹ and Richard B. Warren¹⁰, ¹SKiN Centre for Dermatology, Queen's University, & Probity Medical Research, Peterborough, ON, ON, Canada, ²Austin Institute for Clinical Research, Sanova Dermatology, Austin, TX, USA, Austin, TX, ³Innovaderm Research, Montreal, QC, Canada, Montreal, QC, ⁴Chang Gung Memorial Hospital & Chang Gung University, Taoyuan City, Taiwan, Taoyuan City, Taiwan (Republic of China), ⁵University of Toronto, Lynde Institute for Dermatology & Lynderm Research Inc, Markham, ON, Canada, ON, Canada, ⁶Dermatology Practice Dr. M Hoffmann, Witten, Germany, Witten, Germany, ⁷Department of Dermatology and Department of Medicine, UT Southwestern Medical Center, Dallas, TX, ⁸Frontier Derm, Mill Creek, WA, USA, WA, ⁹Johnson & Johnson, Spring House, PA, USA, Spring House, PA, ¹⁰Dermatology Centre, Northern Care Alliance, NHS Foundation Trust & Division of Musculoskeletal and Dermatological Sciences, Manchester Academic Health Science Centre, University of Manchester, Manchester, United Kingdom
Background/Purpose: Icotrokinra (ICO), a first-in-class, targeted oral peptide that binds and inhibits the interleukin (IL)-23R, was evaluated in ICONIC-TOTAL (NCT06095102).Methods: This Phase 3 trial included…
Abstract Number: 0981 • ACR Convergence 2025
GNTI-350: A CAR-Treg Therapy Offering Durable Immune Reset with Improved Safety for B Cell–Driven Autoimmune Diseases
Christopher Moore¹, Travis Drow², Peter Cook², Annaiz Grimm², Victoria DeVault-Nelson¹, Jennifer Mellen¹, Payam Zarin¹, Alaina Burgess¹, Maegan Hoover¹, Tingxi Guo¹, Brock McKinney², Noelle Dahl², Aesha Vakil², Brian Christin³, Gene Uenishi¹, Tiffany Chen¹, Alberto Del Rio-Espinola⁴, David Rawlings² and Tom Wickham¹, ¹GentiBio, Cambridge, ²SCRI, Seattle, ³GentiBio, Seattle, ⁴GentiBio, Basel, Switzerland
Background/Purpose: CD19 CAR T therapies have demonstrated promise in systemic lupus erythematosus (SLE) by transiently depleting B cells and resetting the immune system. However, long-term…
Abstract Number: 1155 • ACR Convergence 2025
Zasocitinib (TAK-279), an Investigational, Oral, Allosteric, Selective TYK2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis: Efficacy Analysis by Baseline Characteristics from a Randomized Phase 2b Trial
Nada Elbuluk¹, Melinda J. Gooderham², Jessamyn Blau³, Wenwen Zhang³, Ejim Mark³, Warren Winkelman³ and Mark Lebwohl⁴, ¹Department of Dermatology, USC Keck School of Medicine, Los Angeles, CA, ²SKiN Centre for Dermatology, Queen's University, & Probity Medical Research, Peterborough, ON, ON, Canada, ³Takeda Development Center Americas, Inc., Cambridge, MA, ⁴Icahn School of Medicine at Mount Sinai, New York, NY
Background/Purpose: Zasocitinib (TAK-279) is an investigational, highly selective and potent, oral, allosteric tyrosine kinase 2 (TYK2) inhibitor. In a phase 2b trial of moderate-to-severe plaque…
Abstract Number: 1724 • ACR Convergence 2025
Pathogenic role of Mucosal-Associated Invariant T cells in Rheumatoid Arthritis.
Manon LESTURGIE-TALAREK¹, Virginie Gonzalez², Anne Cauvet², Lucie Beaudoin³, Fiona Oudart⁴, Adrien Schvartz⁵, Francesco Carbone⁵, Mickael Menager⁵, Noémie Sénot³, Francoise Tilotta⁶, Yannick Allanore⁷, Agnes Lehuen⁸ and Jérôme AVOUAC⁹, ¹Paris University, Paris, France, ²INSERMU¹⁰¹⁶, Paris, France, ³Institut Cochin, Paris, ⁴APHP - Cochin hospital, Paris, France, ⁵Institut Imagine, Paris, ⁶Université Paris Cité, Montrouge, France, ⁷Université Paris Cité, Paris, France, ⁸Hôpital Cochin, Paris, France, ⁹Rheumatology department, Cochin hospital, Paris, France
Background/Purpose: Mucosal-associated invariant T (MAIT) cells are innate-like lymphocytes that produce cytokines and cytotoxic molecules. Reduced frequencies and altered phenotypes of MAIT cells have been…
Abstract Number: 2023 • ACR Convergence 2025
Isolated Anti-Ro52 Antibody Positivity Is Associated with Increased Cancer Risk and Distinct Malignancy Patterns: A Retrospective Cohort Study from a Single Tertiary Center
Carmen Secada-Gómez¹, Ligia Gabrie-Rodriguez², Hector Ulloa-Alvarado³, Giuliano Boselli⁴, Camilo Veloza-Morales⁵, Diana Prieto-Peña⁶, juan Irure-Ventura⁷, Marcos López-Hoyos⁸ and Ricardo Blanco¹, ¹Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain, ²Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain, ³Servicio Cántabro de Salud, Atención Primaria, Santander, Spain, Santander, Cantabria, Spain, ⁴Rheumatology Division, Hospital Universitario Miguel Servet , Zaragoza, Spain, Zaragoza, Aragon, Spain, ⁵Rheumatology Division, Hospital Universitario Joan XXIII, Tarragona, Spain, Tarragona, Catalonia, Spain, ⁶Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Santander, Spain, ⁷Division of Immunology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Cantabria, Spain, ⁸Division of Immunology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain
Background/Purpose: Anti-Ro52 antibodies are frequently detected in patients with systemic autoimmune rheumatic diseases (SARDs). Emerging evidence suggests a potential link between isolated anti-Ro52 positivity and…
Abstract Number: 2463 • ACR Convergence 2025
Allogenic anti- CD19 CAR-T cells induce remission in refractory systemic lupus erythematosus
Chunnei Yang¹, Chuanyin Sun², Binghe Tan³, Chao Hu¹, Liyan Wan², Changling Xie³, Qian Tan³, Mingyao Liu³, Jin Lin², Bing Du³ and Hongyan Tong¹, ¹Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China (People's Republic), ²Department of Rheumatology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China (People's Republic), ³BRL Medicine Inc., Shanghai, Shanghai, China (People's Republic)
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease associated with significant morbidity and mortality. The treatment approach for SLE primarily involves immunomodulation and…
Abstract Number: 0262 • ACR Convergence 2025
Preclinical Characterization of ABB071 – a Humanized anti-CD180 Antibody that Modulates Multiple Pro-inflammatory Immune Pathways for the Treatment of Autoimmune and Inflammatory Disorders
Margaret McDaniel, Brenda Stevens, Socheath Khim, Alan Wahl, Che-Leung Law and Edward Clark, Abacus Bioscience, Seattle, WA
Background/Purpose: CD180 is a Toll-like receptor (TLR) homolog expressed on antigen-presenting cells (APCs): B cells, dendritic cells, monocytes, and macrophages. While the extracellular domain of…
Abstract Number: 0574 • ACR Convergence 2025
Bimekizumab 3-Year Efficacy In Patients With Psoriasis And Risk Factors For Progression To Psoriatic Arthritis Or Screening Positive For Psoriatic Arthritis: Long-Term Results From Five Phase 3/3b Trials
Richard G. Langley¹, Joseph F Merola², Diamant Thaçi³, Emi Nishida⁴, Bruce Strober⁵, Richard B. Warren⁶, José M. López Pinto⁷, Christina Crater⁸, Sarah Kavanagh⁸ and Paolo Gisondi⁹, ¹Dalhousie University, Halifax, NS, Canada, ²Department of Dermatology and Department of Medicine, UT Southwestern Medical Center, Dallas, TX, ³Institute and Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, Germany, ⁴Nagoya City West Medical Center, Nagoya, Japan, ⁵Department of Dermatology, Yale University, New Haven, and Central Connecticut Dermatology Research, Cromwell, CT, ⁶Dermatology Centre, Northern Care Alliance, NHS Foundation Trust & Division of Musculoskeletal and Dermatological Sciences, Manchester Academic Health Science Centre, University of Manchester, Manchester, United Kingdom, ⁷UCB, Madrid, Spain, ⁸UCB, Morrisville, NC, ⁹Section of Dermatology and Venereology, Department of Medicine, University of Verona, Verona, Italy
Background/Purpose: Psoriatic arthritis (PsA) affects up to one-third of patients with psoriasis;1 early identification and intervention for patients with psoriasis and risk factors (RFs) for…
Abstract Number: 0982 • ACR Convergence 2025
Impact of Immunosuppressive Therapies on Shingrix Vaccine Response in Immune-Mediated Inflammatory Diseases
cristiana Sieiro¹, Juan García Herrero², Jose Ordas Martínez³, Carolina Álvarez Castro³, Alejandra López Robles³, Ronald Colindres³, Ana María Sahagún⁴ and Jose María Ruiz de Morales³, ¹Univrsity of Manchester, Manchester, United Kingdom, ²complejo asistencial universitario de leon, León, Spain, ³Complejo Asistencial Universitario de León, León, Spain, ⁴University of Leon, León, Spain
Background/Purpose: Herpes zoster (HZ) is a common infection, particularly in older adults and women, and can lead to complications like neuropathic pain. The risk is…
Abstract Number: 1163 • ACR Convergence 2025
Clinical and Biomarker Characteristics of Inebilizumab-Treated Participants Who Experienced an IgG4-RD Flare During the Phase 3 MITIGATE Trial
John Stone¹, Emma Culver², Arezou Khosroshahi³, Wen Zhang⁴, Emanuel Della Torre⁵, Kazuichi Okazaki⁶, Yoshiya Tanaka⁷, Matthias Lohr⁸, nicolas schleinitz⁹, Fernando Martinez-Valle¹⁰, Manu Nayar¹¹, Vinciane Rebours¹², Cory Perugino¹³, Kristen Clarkson¹⁴, Theresa Alexander¹⁴, Xinxin Dong¹⁴, Qian Huang¹⁴, Sue Cheng¹⁴ and Daniel Cimbora¹⁴, ¹Massachusetts General Hospital , Harvard Medical School, Concord, MA, ²John Radcliffe Hospital; University of Oxford, Oxford, United Kingdom, ³Emory University, Atlanta, GA, ⁴Peking Union Medical College Hospital, Dong Cheng Qu, China (People's Republic), ⁵IRCCS San Raffaele Scientific Institute, Milan, Italy, ⁶Kansai Medical University Kori Hospital, Osaka, Japan, ⁷University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ⁸Karolinska Institutet, Stockholm, Sweden, ⁹Aix Marseille university, AP-HM, Marseille, France, ¹⁰Vall d’Hebron Hospital, Barcelona, Spain, ¹¹Freeman Hospital, Newcastle upon Tyne, United Kingdom, ¹²Beaujon Hospital, AP-HP, Université Paris-Cité, Clichy, France, ¹³Massachusetts General Hospital, Harvard Medical School, Boston, MA, ¹⁴Amgen, Thousand Oaks, CA
Background/Purpose: IgG4-RD is a rare, chronic, fibroinflammatory disorder characterized by recurrent flares that can affect any organ and lead to permanent tissue damage. Inebilizumab (INEB)…
Abstract Number: 1726 • ACR Convergence 2025
Inflammatory arthritis immune related adverse events represent a unique autoimmune disease entity primarily driven by T cells, but likely not autoantibodies
Xingxing Zhu¹, yue Yu¹, Yangfen Li¹, Panwen wang², ying li², Chantal McCabe², shiju chen², Brenna Sharp², Amber Wolzen², Hannah Langenfeld¹, Andrew C. Hanson¹, Cynthia Crowson³, svetomir Markovic², John Davis¹, Haidong Dong², Uma Thanarajasingam¹ and Hu Zeng¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Rochester, ³Mayo Clinic, Stewartvillle, MN
Background/Purpose: The immunological basis of inflammatory arthritis (IA) immune related adverse event (irAE) following anti-PD-1/PD-L1 immune checkpoint inhibition (ICI) therapy is incompletely understood. The relationship…
Abstract Number: 2033 • ACR Convergence 2025
Complement Fragments are Deposited in the Submandibular Glands in IgG4-Related Disease
Guy Katz¹, Judith Ferry¹, Grace McMahon¹, Isha Jha², Claire Galand³, Fei Liu⁴, Shelia Violette⁴, Jason Campagna⁴, Ana Fernandes¹, Cory Perugino⁵ and John Stone⁶, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Boston, ³Q³² Bio Inc,, Waltham, MA, ⁴Q³² Bio Inc, Waltham, MA, ⁵Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁶Massachusetts General Hospital , Harvard Medical School, Concord, MA
Background/Purpose: Hypocomplementemia, defined as low serum C3 and/or C4 concentrations, is common in patients with IgG4-related disease (IgG4-RD). While this has historically been linked with…
Abstract Number: 2498 • ACR Convergence 2025
Effect of autologous myeloablative hematopoietic stem cell transplantation on skin and peripheral blood mononuclear cells in systemic sclerosis patients with interstitial lung disease
Poulami Dey¹, Rachael Bogle², Qinmengge Li³, Olesya Plazyo⁴, Rosemary Gedert⁴, Carleigh Zahn⁴, Pei-Suen Tsou⁴, John Varga⁴, Lam Tsoi⁴, Johann Gudjonsson⁴ and Dinesh Khanna⁴, ¹Michigan Medicine, Ann Arbor, MI, ²University of Michigan, Holland, OH, ³University of Michigan, Ypsilanti, MI, ⁴University of Michigan, Ann Arbor, MI
Background/Purpose: Systemic sclerosis (SSc) is characterized by skin fibrosis, dysregulated immune response, and vascular system dysfunction. Interstitial lung disease (ILD) is one of the leading…

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].